Technical analysis of Larimar Therapeutics, Inc. (LRMR): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials.
Price Performance
| 1 month | -4.56% |
| 3 months | +6.46% |
| Year-to-date | +1.71% |
| 1 year | -5.02% |
| 3 years | -5.95% |
| 5 years | -69.32% |
52-Week Range
| 52-week High | $6.42 |
| 52-week Low | $2.72 |
| Avg Volume (90d) | 1.8M |
Technical Indicators
| SMA 50 | $3.98 |
| SMA 200 | $3.95 |
| Beta | 1.02 |
| 30-day Volatility (annualised) | 50.9% |
| Price vs SMA 50 | -2.8% |
| Price vs SMA 200 | -1.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.89 | |
| 2025-11 | $3.54 | -9.0% |
| 2025-12 | $3.81 | +7.6% |
| 2026-01 | $3.54 | -7.1% |
| 2026-02 | $5.31 | +50.0% |
| 2026-03 | $4.50 | -15.3% |
| 2026-04 | $4.06 | -9.8% |
| 2026-05 | $3.48 | -14.3% |
| 2026-06 | $3.05 | -12.4% |
| 2026-07 | $3.82 | +25.2% |
| 2026-08 | $3.82 | +0.0% |
| 2026-09 | $3.88 | +1.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $3.93 |
| Market Cap | $408M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.23 |
| EV / EBITDA | -1.85 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 4.70 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -4.98 |